Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry.

Autor: Hatziagorou E; Cystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece., Fieuws S; KU Leuven - University of Leuven, Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium., Orenti A; Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Biometry and Epidemiology 'G.A. Maccacaro', University of Milan, Milan, Italy., Naehrlich L; Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany., Krivec U; Department of Paediatric Pulmonology, University Children's Hospital Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia., Mei-Zahav M; Pulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Jung A; Paediatric Pulmonology, University Children's Hospital Zurich, Zurich, Switzerland., De Boeck K; Paediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium.
Jazyk: angličtina
Zdroj: ERJ open research [ERJ Open Res] 2023 May 22; Vol. 9 (3). Date of Electronic Publication: 2023 May 22 (Print Publication: 2023).
DOI: 10.1183/23120541.00449-2022
Abstrakt: Aim: To examine the trajectory of forced expiratory volume in 1 s (FEV 1 ) using data from the European Cystic Fibrosis Society patient registry (ECFPR) collected from 2008 to 2016, i.e. the era before highly effective modulator therapy (HEMT). We evaluated risk factors for FEV 1 decline.
Methods: The study population included patients with a confirmed diagnosis of cystic fibrosis recorded in the ECFPR (2008-2016). The evolution of FEV 1 % predicted (%FEV 1 ) with age, and the yearly change in %FEV 1 were evaluated. Risk factors considered were cystic fibrosis transmembrane conductance regulator ( -CFTR ) mutation class, gender, age at diagnosis, neonatal screening, meconium ileus, sweat chloride concentration at diagnosis and country's income level.
Results: We used 199 604 FEV 1 recordings from 38 734 patients. The fastest decline was seen during puberty and in patients diagnosed before the age of 10 years. Males had a higher %FEV 1 , but a higher yearly %FEV 1 loss between the ages of 15 and 25 years. We showed stabilisation and even improvement in %FEV 1 over age in adults with a class III CFTR mutation, but a steady decline in patients homozygous for F508del or with both mutations of classes I/II. A faster decline in %FEV 1 was found in patients from low-income countries compared to a similar %FEV 1 evolution in patients from middle- and high-income countries.
Conclusions: These longitudinal FEV 1 data reflect the reality of cystic fibrosis across Europe in the era pre-HEMT, and can serve as baseline for comparison with the post-HEMT era. The similar evolution in middle- and high-income countries underlines opportunities for low-income countries.
Competing Interests: Conflict of interest: The authors declare no conflict of interest.
(Copyright ©The authors 2023.)
Databáze: MEDLINE
Externí odkaz: